CYTEK BIOSCIENCES, INC. (CTKB)

Every figure this model derived for CTKB, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 6,042,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 73,846,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 377,931,000 AssetsCurrent 2026-06-30
current liabilities 84,335,000 LiabilitiesCurrent 2026-06-30
equity 321,954,000 StockholdersEquity 2026-06-30
interest expense 474,000 InterestExpenseNonoperating 2025-12-31
ocf -6,038,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 206,709,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 21,365,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up CTKB on one particular measure came for.

RatioValue
cash operating margin-7.54
current ratio6.86
current ratio reported4.48
deferred revenue growth3.83
dilution pct-2.2
fcf margin-5.84
growth cv0.8
interest cover-94.2
operating margin-21.6
owner earnings margin-16.18
revenue growth5.44
revenue growth per share7.81
roic-14.22
rpo growth5.61
rule of 40-16.15
sbc pct revenue10.34

What to be careful about

What this model itself distrusts about CTKB's figures. Written by the derivation as it ran, not added afterwards.